NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Sunday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NYSE NBY opened at $0.70 on Friday. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08. The company has a 50-day moving average of $0.62 and a 200-day moving average of $0.84. The company has a market cap of $3.42 million, a P/E ratio of -0.01 and a beta of 0.65.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.